Sandoz deal bolsters Aurobindo on derma

Aurobindo says it is continuing to focus its efforts on driving profitability through a “differentiated portfolio”, with a particular focus on dermatology, after striking in early September a US$1.0 billion deal to acquire Sandoz’ dermatology and oral-solids business in the US.